Lapatinib (Tyverb): important update to the therapeutic indication and Summary of Product Characteristics

Dear Healthcare Professional,

Novartis Europharm Ltd. in agreement with the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency (MHRA) would like to inform you of the following:

**Summary**

- The therapeutic indication (section 4.1 lapatinib Summary of Product Characteristics) has been amended to reinstate the information that *there is no data on the efficacy of lapatinib relative to trastuzumab, both used in combination with an aromatase inhibitor, in postmenopausal women with hormone receptor positive metastatic disease previously treated with trastuzumab or an aromatase inhibitor.*
- Corresponding information that relates to the results of Study EGF114299, has been deleted from section 5.1 of the SmPC.
- These changes are due to the detection of errors in the efficacy results of Study EGF114299. This study evaluated the efficacy and safety of lapatinib in combination with an aromatase inhibitor in postmenopausal women who had HR+/HER2+ metastatic breast cancer which had progressed after prior trastuzumab-containing chemotherapy regimen and endocrine therapies.
- For patients who are currently receiving lapatinib in combination with an aromatase inhibitor, who have previously progressed on trastuzumab containing therapy, an evaluation of benefit-risk and a decision on continuation of therapy should be made on a case-by-case basis.

**Background**

Currently, lapatinib (Tyverb) is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2):

- in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.
- in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy.
- in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy.

Following the granting of the initial marketing authorisation, study EGF114299 was conducted to fulfill a post-approval commitment to evaluate the efficacy and safety of Tyverb in combination with an aromatase inhibitor in postmenopausal women who had hormone receptor-positive/ HER2-positive metastatic breast cancer which had progressed after prior trastuzumab-containing chemotherapy regimen and who had previously received endocrine therapy. Results were reflected in SmPC section 5.1 Pharmacodynamic Properties. The indication statement was also amended at that time, to remove the statement that no data are available on relative efficacy versus trastuzumab-based combination therapy in such a population.

Programming errors were identified in study EGF114299 primarily affecting the comparison between lapatinib + aromatase inhibitor and trastuzumab + aromatase inhibitor, erroneously suggesting a relative benefit of lapatinib
over trastuzumab. In order to address this and in agreement with EMA, the results of study EGF114299 have been removed from section 5.1 of the SmPC and the statement relating to lack of availability of comparative efficacy data has been reinstated in the Indication. An assessment of the corrected data is ongoing at this time.

For patients who have previously progressed on trastuzumab who are receiving lapatinib in combination with an aromatase inhibitor currently, an evaluation of benefit-risk and a decision on continuation of therapy should be made on a case-by-case basis.

There are no additional safety concerns related to use of lapatinib-based regimens.

Call for reporting

Please continue to report suspected adverse drug reactions (ADR’s) to the MHRA through the Yellow Card Scheme. Please report all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason.

It is easiest and quickest to report ADRs online via the Yellow Cards website - https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, prepaid Yellow Cards for reporting are available:

- by writing to FREEPOST YELLOW CARD (no other address details necessary)
- by emailing yellowcard@mhra.gov.uk
- at the back of the British National Formulary (BNF)
- by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789
- or by downloading and printing a form

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the patient safety information (PSI) tool at https://psi.novartis.com/.

Company contact points

If you have any questions or require further information, please contact Novartis Medical Information department on 01276 698370 or email medinfo.uk@novartis.com.

Yours faithfully,

Dr James Warburton
Country Medical Director, Oncology

Novartis Pharmaceuticals UK Limited
Park View, Riverside Way
Watchmoor Park
Camberley, Surrey, GU15 3YL, UK